[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nsclc-stage-iiibiv\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nsclc-stage-iiibiv":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":27,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100604521","immune-marker-platform-for-patients-with-advanced-lung-cancer-100604521",false,"NCT07150598","Immune-Marker Platform for Patients With Advanced Lung Cancer","IMPALUX","Inclusion Criteria:\n\nFor all:\n\n* Written informed consent of the patient\n* Consent of participation in the national Network for Genomic Medicine in Lung Cancer (nNGM)\n* Advanced lung cancer with non-curative treatment option (NSCLC)\n* No targetable driver mutation detected, defined as no targetable drive mutation in ALK, EGFR, BRAF, HER2, MET, NTRK, RET, ROS1\n* PD-L1 expression on tumor cells (TPS \\\u003C 50%)\n\nCohort A:\n\n* Previously untreated NSCLC without curative treatment options\n* Sufficient pre-treatment tumor material available for the planned analyses or consenting and able to undergo additional pretreatment biopsy\n* Scheduled to undergo immune(chemo)therapy\n* Willing and able to undergo re-biopsy 6 weeks after start of immune(chemo)therapy\n\nCohort B:\n\n* Any line of progression after firstline immune(chemo)therapy\n* Sufficient tumor material obtained after progression on most recent line of treatment available or willing and able to undergo re-biopsy prior to next line treatment\n\nExclusion Criteria:\n\n* Any condition representing an unjustified risk for obtaining an additional biopsy sample (if needed) in the view of the investigator\n* Incapability of understanding the purpose and possible consequences of the trial\n* Substance abuse, medical, psychological or social conditions that may interfere with the subject's cooperation with the requirements of the trial or evaluation of the study results","ALL","18 Years",{"count":19,"type":20},500,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to better understand how the immune system and certain tumor markers are linked to treatment response in patients with advanced non-small cell lung cancer (NSCLC) who receive immunochemotherapy.\n\nThe investigators aim to answer the following questions:\n\n* Can the investigators successfully analyze immune markers and gene activity from small tumor samples (biopsies)?\n* Are these markers connected to how well patients respond to immunochemotherapy and how their disease progresses?\n\nWhat will participants do?\n\n* Provide tumor tissue samples (biopsies) at key points: before treatment, about 6 weeks after starting immunochemotherapy, and if the cancer grows or treatment changes.\n* Allow their tumor samples to be analyzed in the lab using advanced techniques to measure immune and genetic markers.\n* Share clinical information (such as treatment response and disease progression) so investigators can study how it relates to these markers.\n\nThis study does not test a new drug or treatment.",[24,25,26],"NSCLC (Advanced Non-small Cell Lung Cancer)","NSCLC Stage IIIB~IV","NSCLC Non-small Cell Lung Cancer",[28,29,30,31,32,33,34,35,36],"Non-Small Cell Lung Cancer","NSCLC","Immunochemotherapy","Multiplex Immunofluorescence","3'-RNA Sequencing","Prospective Observational Study","Tumor Microenvironment","Therapy Response","Precision Oncology","NOT_YET_RECRUITING","2025-09-01",{"date":40,"type":41},"2025-09-08","ACTUAL",{"date":38,"type":20},{"date":44,"type":20},"2027-06-01",{"name":46,"class":47},"Technische Universität Dresden","OTHER",2]